Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, details exciting findings from the EMPOWER-Lung 1 trial regarding cemiplimab and patients with non–small cell lung cancer (NSCLC). One of the ...
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone ...
TARRYTOWN, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...
TORONTO, March 6, 2025 /CNW/ - Regeneron Canada Company announced today that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the reimbursement of ...
Regeneron Pharmaceuticals Inc announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo ...
KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II–IIIB (N2) non–small-cell lung cancer (NSCLC) ...
Please provide your email address to receive an email when new articles are posted on . A significant correlation was found in patients treated with radiotherapy prior to cemiplimab. A ‘potential ...
While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...
TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo ® (cemiplimab) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback